@dmuthuk As if Vijay himself calls and tells Mr Muthu that he his "this vision" and "that vision". What Mr Muthu is conducting is a masterclass in how to shape a group of people's thinking and mindset favouring a specific direction. 👏🏻👏🏻👏
@TheStalwart@adamjkucharski A true analysis would include a bunch of humans read it and give their perspective. I wouldn’t be surprised if they pulled a copilot..
@georgeviews@TVKVijayHQ Did you read the Order shared by you?
Did you saw the date of the G. O?
It is 13.08.2025
This proposal to NABARD bank was initiated by DMK last year and Fund came now.
Nothing done by TVK now other than releasing fund received from NABARD
@tnrags@the_hindu@cpimspeak@MABABYCPIM Considering a proposal is not the same as accepting it. Such alliances happen all the time when there is a tripolar or quadripolar competiton (Germany- grand coalition, Austria, Israel). Did we get disgusted when congress/left/VCK joined TVK?
A sobering statistic from the BLS highlights another dimension of the Main Street/Wall Street divide:
The US labor share of output fell to 54.1% in Q1 2026, the lowest level since this data series began in 1947.
Put another way, labor is consistently capturing a declining share of the value created by productivity gains, with the benefits increasingly accruing to the owners of capital.
#economy #markets #labor #productivity
இந்த மனுஷனை பாத்தா பிரம்மிப்பா இருக்கு 🥹
வேற யாராவது இருந்திருந்தா அந்த தொகுதி பக்கம் எட்டி கூட பாத்திருக்க மாட்டாங்க
அடுத்த நாளே போயி நிக்கிறாரு 🙏
இன்னா செய்தாரை ஒறுத்தல் அவர்நாண
நன்னயஞ் செய்து விடல்..
#MkS 🏴🚩
if every doctor in the US worked for free, healthcare costs would go down ~8%
meanwhile:
MSOs take ~20–30% of practice revenue
TPA/ASOs take ~10% of insurance premiums
the US has built an enormous economy around healthcare without adding much more care
@rajan_brainsurg@DeviYogha@mkstalin This is an opportunity for the rationalism to reinvent itself for the AI age. The job of political commentators is to educate youth. I had a grand father who educated me on politics and women power. We should engage with the youth of TN.
I know some have become experts at clinical appraisal and clinical trial critique. It’s important to have this dialogue and it helps physicians and patients understand the drawbacks of a given trial. But my advise to young investigators is to best not to make it your primary academic output.
Secondly, when critiquing it’s also worthwhile remembering that the investigators of trials may also fully aware of the issues but there are many barriers and often we have to choose between not doing a trial at all versus compromising. Perfect trials are not common; we can usually find some fault with almost all trials. So we must strive to avoid rudeness and condescension.
Third, try if possible to lead a clinical trial or at least get engaged with someone who leads trials and get a feel for the various stakeholders who have veto power during trial design, and more importantly the various competing priorities for what the trial seeks to accomplish, it will be easier to understand why a specific control arm was chosen, or a why a specific endpoint was chosen, even though you may think they are the wrong ones.
Dearest gentle reader, we are delighted to announce a new story from our lab published in @Nature describing how a meal's systemic metabolic changes are interpreted by your immune system to enhance adaptive immunity. A thread 1/ https://t.co/zACqCLxDMU
Not a good take . Each drug improving OS over the current SoC will add up incrementally.
Don’t be a nihilist. You can live in Cuba and blame capitalism all you want in that case .
Pharma, for all its warts , deserves lot of accolades for doing risky studies and showing positive results .
There is no one size fits all magic cure out there for stage IV cancers .Incremental progress should be applauded.
Dr. Urun This is not really a model competition. It is a constraint system.
H&E AI can approximate what assays like Oncotype DX are doing. That is clear. Morphology carries real signal.
But oncology decisions are not made on approximation alone. They are made on validated, defensible assays that are embedded in guidelines and can be justified clinically and legally.
So the field actually sits across three layers:
H&E AI as the efficient, low cost signal layer
Oncotype DX as the incumbent, guideline backed decision layer
New multi-omic approaches like Caris MI Clarity, which combine pathology with DNA and RNA to provide deeper biological resolution, but are still earning decision level trust
The key point is that better prediction alone does not drive adoption. Accountability does.
That is why H&E will not immediately replace Oncotype, even if it gets close. And it is why newer approaches like MI Clarity by Caris have to prove not just that they are more informative, but that decisions based on them are safe and defensible.
The transition will be layered. Efficiency expands first, but the decision layer only shifts when guidelines and trust follow.
@dvasishtha Get your data right ..
HCA expanding residency slots by 7000 and making money exploiting tax payers ..
NPs keep switching specialities , stay in same urban areas and drive up the cost of care with unnecessary referrals..
Just a reminder that the healthcare costs that are hitting most people’s pockets are not from independent physicians. It’s from insurers and healthcare systems buying up physicians who can’t make it in today’s economic environment. Physicians are down 35+% in the last decade as far as pay. Insurers are posting record profits.